Pregabalin Capsule
Product Images NDC 71610-758

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-758). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 75 mg (71610 0758 30)

Pregabalin 75 mg oral capsules package label showing 30 capsules. The label includes the NDC number 71610-0758-30 and storage instructions to keep between 20-25 degrees Celsius. Manufactured by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also contains batch and expiration information, and a warning about potential habit forming. The label indicates prescription use only.*

FDA Label Image

Bottle Label 200 mg (71610 0759 30)

Packaging label for Pregabalin 200 mg oral capsules by Aphena Pharma Solutions - Tennessee, LLC. The label indicates a package containing 30 capsules, with storage instructions between 20-25°C (68-77°F) and a requirement to protect from light. The label includes an NDC number and manufacturing details from MSN Laboratories Private Limited.*

FDA Label Image

Bottle Label 225 mg (71610 0760 46)

Pregabalin 225 mg capsule bottle label showing 56 capsules per bottle. The label includes storage instructions to keep at 20-25°C (68-77°F) and to keep out of reach of children. The manufacturer is Aphena Pharma Solutions - Tennessee, LLC, with the labeler listed as MSN Laboratories Private Limited, Telangana, India. The label also shows the NDC number 71610-0760-46 and warns that the product is for oral use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

A text panel showing the formula for calculating creatinine clearance (CLCr) as a function of age, weight, and serum creatinine levels, with an adjustment factor for female patients. The formula includes terms for age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting the percent of patients improved versus the percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, with the y-axis showing percent of patients improved and the x-axis showing percent improvement in pain.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A survival-type plot chart comparing percent of patients improved versus percent improvement in pain from baseline, contrasting Pregabalin 100 mg three times a day (dashed line) with placebo (dotted line). The y-axis represents the percent of patients improved, and the x-axis shows percent improvement thresholds from >0 to 100.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day compared to placebo. The graph illustrates a trend where higher doses correspond to a greater percent of patients improved across pain improvement percentages.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares the effectiveness of two Pregabalin dosages against placebo across a range of pain improvement percentages.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line chart illustrating the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line), showing relative efficacy over a range of pain improvement percentages.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart comparing responder rates (%) between placebo and various Pregabalin dosing regimens from two studies (E1 and E3). Study E1 shows increasing responder rates with doses from 50 mg to 600 mg per day (BID), while Study E3 compares placebo with 600 mg per day given BID and TID. The chart includes sample sizes (N) below each group and notes statistical significance versus placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. Four treatment groups (Stukly E1BID, Stukly E2BID, Stukly E3BID, Stukly E3TID) are plotted with different symbols. Data points show seizure reduction increasing with dose, with significant p-values indicated at various points. The x-axis represents daily dose (0, 50, 150, 300, 600 mg/day) and the y-axis shows seizure reduction percentage up to 60%.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph presenting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis, comparing Pregabalin daily doses of 600 mg, 450 mg, and 300 mg with placebo. The graph shows four curves illustrating patient improvement trends for each dosage and placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve comparing Pregabalin and Placebo. The y-axis shows the estimated percentage of subjects without LTR (loss to response), ranging from 0% to 100%. The x-axis represents the number of days, from 0 to 180. The solid line depicts Pregabalin, and the dashed line depicts Placebo, illustrating differences in subject retention over time.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over different percentages improved from baseline to week 12 using BOCF method. It shows two lines, one for Pregabalin and another for Placebo, with the Pregabalin line consistently higher, indicating a greater percentage of subjects improved compared to Placebo across the range.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved in a study of Pregabalin versus placebo. The x-axis shows percent improvement from baseline to week 16 BOCF, ranging from 0 to over 100%. The y-axis shows the percent of subjects improved, from 0 to 100%. Two lines represent Pregabalin (solid) and placebo (dotted), with Pregabalin showing a higher percent of subjects improved at various improvement thresholds.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of Pregabalin. The diagram depicts the molecular arrangement of atoms including carbon, hydrogen, nitrogen (NH2), and oxygen (O) groups relevant to the active ingredient Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.